Lupin launches Tolvaptan Tablets in the US with 180-day exclusivity
Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
ISPP will analyze health systems across states, identifying scalable models and actionable insights to strengthen India's healthcare delivery
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
This marks yet another milestone in our series of successful audits over the past year
Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
30th Lab in Thyrocare’s expanding network to bring advanced, affordable diagnostics in Bihar and beyond
This significant milestone enhances our global regulatory standing
The FDA issued Form 483 with one observation related to building and facility management
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Subscribe To Our Newsletter & Stay Updated